Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib safety study for prevention of bowel perforation in platinum-resistant ovarian cancer
2016-004618-93Phase 2Unknown
- Sponsor
- The University of Manchester
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cediranib in ovarian cancer (2 arms), sponsored by The University of Manchester. Primary endpoint: Freedom from grade III-V gastrointestinal perforation or fistula. Status: unknown.
02
Drugs
cediranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2016-004618-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004618-93.